Peptide Research: Current Evidence and Future Directions in Regenerative Medicine

The landscape of peptide research has undergone substantial transformation over the past decade, evolving from theoretical constructs to clinically validated therapeutic modalities. Structural peptides, particularly those targeting extracellular matrix (ECM) repair and regeneration, represent a convergence of molecular biology, materials science, and clinical dermatology. This review synthesizes current evidence from clinical trials, mechanistic studies, and emerging therapeutic applications that define the state of peptide therapeutics in regenerative aesthetics.

The extracellular matrix serves as both a structural scaffold and a dynamic signaling environment that regulates cellular behavior, tissue homeostasis, and regenerative capacity. Age-related degradation of ECM components—particularly collagens, elastin, and glycosaminoglycans—manifests as visible tissue atrophy, loss of mechanical integrity, and impaired wound healing.¹ Peptide-based interventions offer targeted approaches to address these degenerative processes through multiple mechanisms: stimulation of endogenous biosynthetic pathways, inhibition of proteolytic degradation, and direct structural reinforcement of the ECM architecture.

Current State of Structural Peptide Research

Contemporary peptide research encompasses diverse molecular architectures and functional mechanisms, ranging from signal peptides that modulate gene expression to matrikines derived from ECM protein fragments. The field has progressed from empirical screening approaches to rational design strategies informed by structural biology and computational modeling.

Signal Peptides and Growth Factor Mimetics

Signal peptides function as molecular messengers that activate specific cellular receptors and downstream signaling cascades. Palmitoyl pentapeptide-4 (Matrixyl), among the most extensively studied cosmetic peptides, demonstrates significant effects on collagen synthesis through activation of transforming growth factor-beta (TGF-β) signaling pathways.² In vitro studies have documented up to 350% increases in Type I collagen production and 200% increases in fibronectin synthesis in cultured fibroblasts exposed to palmitoyl pentapeptide-4 at concentrations of 3-5 ppm.

Subsequent research has elucidated the molecular mechanisms underlying these effects. The peptide sequence Lys-Thr-Thr-Lys-Ser represents a cryptic matrikine sequence derived from the C-terminal region of Type I collagen, which naturally occurs during collagen turnover. This sequence binds to specific integrin receptors on fibroblast membranes, triggering conformational changes that activate focal adhesion kinase (FAK) and subsequent mitogen-activated protein kinase (MAPK) signaling cascades.³ The palmitoyl modification enhances membrane permeability and extends the peptide's biological half-life in the dermal microenvironment.

Copper Peptides and Tissue Remodeling

Copper peptides, particularly GHK-Cu (glycyl-L-histidyl-L-lysine-copper(II)), exemplify multifunctional peptide therapeutics with distinct mechanisms of action. Originally isolated from human plasma, GHK-Cu demonstrates concentration-dependent effects on tissue remodeling, with low concentrations (nanomolar range) promoting collagen synthesis and higher concentrations (micromolar range) facilitating controlled matrix degradation and remodeling.⁴ This biphasic response reflects the peptide's capacity to modulate both matrix metalloproteinase (MMP) activity and tissue inhibitor of metalloproteinase (TIMP) expression.

Recent genomic studies have revealed that GHK-Cu influences expression of over 4,000 human genes, with particular enrichment in pathways related to collagen synthesis, angiogenesis, and antioxidant response.⁵ The peptide functions as a copper chelator, facilitating copper delivery to lysyl oxidase—a copper-dependent enzyme essential for collagen and elastin crosslinking. Additionally, GHK-Cu demonstrates potent anti-inflammatory properties through suppression of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) production in activated immune cells.

Neurotransmitter-Modulating Peptides

A distinct class of cosmetic peptides functions through modulation of neurotransmitter release at the neuromuscular junction. Acetyl hexapeptide-8 (Argireline), a synthetic peptide inspired by SNAP-25 protein structure, competitively inhibits SNARE complex formation, thereby reducing acetylcholine release and subsequent muscle contraction.⁶ While marketed primarily for expression line reduction, the clinical efficacy remains substantially below that of botulinum toxin, with studies reporting 17-30% reductions in wrinkle depth compared to 80-90% reductions with botulinum toxin type A.

Despite limitations in clinical efficacy, neurotransmitter-modulating peptides have contributed to understanding of topical peptide delivery and skin barrier penetration. Research utilizing Franz diffusion cells and fluorescently labeled peptide analogs has demonstrated that molecular weight, charge distribution, and lipophilicity critically determine dermal bioavailability. These findings have informed development of enhanced delivery systems, including nanoparticle encapsulation, microneedle arrays, and chemical penetration enhancers.

Clinical Trial Evidence for Peptide Therapeutics

Translation of peptide research from bench to bedside requires rigorous clinical validation through randomized, controlled trials. While the cosmetic peptide industry has historically relied on small, open-label studies with limited statistical power, recent years have witnessed increased adoption of robust clinical trial methodologies incorporating objective measurement techniques and appropriate control groups.

Randomized Controlled Trials of Topical Peptides

A double-blind, randomized controlled trial examining palmitoyl pentapeptide-4 cream (0.0005% concentration) versus vehicle control in 93 participants demonstrated statistically significant improvements in multiple aging parameters after 12 weeks of twice-daily application.⁷ Objective measurements using optical profilometry revealed 17% reduction in wrinkle depth (p < 0.01), 23% improvement in skin roughness (p < 0.001), and 12% increase in dermal density measured by high-frequency ultrasound (p < 0.05). Histological analysis of skin biopsies from a subset of participants (n=20) demonstrated 18% increase in epidermal thickness and enhanced organization of dermal collagen fibers visualized through polarized light microscopy.

Similarly, a multicenter trial evaluating acetyl hexapeptide-8 (10% concentration) in 60 participants with moderate to severe forehead wrinkles reported 27% reduction in maximum wrinkle depth after 30 days of treatment, measured by silicon replica analysis and digital imaging.⁸ However, the study lacked a botulinum toxin positive control arm, limiting conclusions regarding comparative efficacy. Subsequent comparative effectiveness research has consistently demonstrated superior outcomes with injectable neuromodulators, positioning topical peptides as maintenance therapies rather than primary interventions for dynamic rhytides.

Combination Therapy Approaches

Recognition of the multifactorial nature of skin aging has driven investigation of combination peptide formulations targeting complementary pathways. A 24-week study examining a multi-peptide complex containing palmitoyl tripeptide-1, palmitoyl tetrapeptide-7, and acetyl hexapeptide-8 demonstrated synergistic effects exceeding those of individual components.⁹ Participants receiving the combination formulation (n=42) exhibited 31% improvement in overall photodamage score, 24% reduction in periorbital wrinkles, and 19% improvement in skin firmness measured by cutometry, compared to 12-15% improvements with single-peptide formulations.

Integration of peptides with established anti-aging interventions has yielded promising results in regenerative aesthetics protocols. Combination of GHK-Cu with fractional laser resurfacing demonstrated accelerated wound healing and reduced post-inflammatory hyperpigmentation compared to laser treatment alone in a randomized split-face study (n=38).¹⁰ The peptide-treated side exhibited 35% faster re-epithelialization, 42% reduction in erythema duration, and superior patient satisfaction scores. These findings support peptides' role in optimizing outcomes from energy-based devices through enhanced tissue repair mechanisms.

Limitations of Current Clinical Evidence

Despite accumulating clinical data, the peptide research field faces persistent methodological challenges that constrain evidence quality. Many published studies suffer from small sample sizes (n<50), short treatment durations (4-12 weeks), industry sponsorship bias, and lack of long-term safety data. The absence of standardized outcome measures across studies complicates meta-analysis and comparative effectiveness assessment. Furthermore, the proprietary nature of commercial formulations—where peptide concentrations, delivery systems, and adjuvant ingredients remain undisclosed—limits reproducibility and mechanistic interpretation of clinical findings.

Addressing these limitations requires adoption of standardized research protocols, establishment of independent clinical trial registries for cosmetic peptide studies, and increased funding for investigator-initiated research. The development of validated biomarkers for ECM homeostasis—including serum procollagen propeptides, circulating matrikines, and non-invasive imaging modalities—would facilitate more objective assessment of peptide therapeutic efficacy.

Molecular Mechanisms of ECM Repair and Regeneration

Understanding the molecular mechanisms underlying peptide-mediated ECM repair provides rational foundation for therapeutic development and clinical application. The extracellular matrix represents a complex, dynamic structure comprising fibrillar proteins, proteoglycans, glycoproteins, and matricellular proteins that collectively regulate tissue architecture and cellular behavior.

Collagen Biosynthesis and Maturation

Collagen synthesis represents a highly regulated, multi-step process vulnerable to age-related decline at multiple control points. Signal peptides influence this process through modulation of gene transcription, mRNA stability, and post-translational modifications. Research has demonstrated that palmitoyl pentapeptide-4 increases COL1A1 and COL3A1 gene expression through activation of TGF-β/Smad signaling pathways and recruitment of transcriptional coactivators to collagen gene promoters.¹¹ This transcriptional activation results in sustained elevation of procollagen synthesis over 48-72 hours following peptide exposure.

Post-translational collagen maturation requires coordinated action of multiple enzymatic systems. Prolyl and lysyl hydroxylases catalyze hydroxylation of proline and lysine residues, enabling triple helix formation and subsequent crosslinking. Lysyl oxidase oxidatively deaminates specific lysine and hydroxylysine residues, generating reactive aldehydes that spontaneously condense to form covalent crosslinks stabilizing collagen fibrils. Copper peptides enhance this process through delivery of bioavailable copper to lysyl oxidase active sites, increasing enzyme activity and crosslink density.¹² The resulting collagen fibrils demonstrate enhanced tensile strength and resistance to proteolytic degradation.

Matrix Metalloproteinase Regulation

Matrix metalloproteinases constitute a family of zinc-dependent endopeptidases responsible for controlled ECM degradation during tissue remodeling, wound healing, and homeostatic turnover. Chronic elevation of MMP activity, particularly MMP-1 (collagenase), MMP-2 and MMP-9 (gelatinases), characterizes both intrinsic aging and photoaging. Certain peptides demonstrate capacity to modulate MMP expression and activity through multiple mechanisms.

Soy peptides and rice peptides have shown inhibitory effects on MMP-1 expression in ultraviolet-irradiated keratinocytes and fibroblasts, mediated through suppression of activator protein-1 (AP-1) transcription factor activity.¹³ This mechanism directly counteracts UV-induced matrix degradation that underlies photoaging. Additionally, specific peptide sequences derived from Type IV collagen demonstrate direct MMP inhibitory activity through competitive binding to enzyme active sites, functioning as substrate mimetics that occupy the catalytic cleft without undergoing proteolysis.

Proteoglycan and Glycosaminoglycan Synthesis

The dermal ECM's hydration capacity and biomechanical properties depend critically on proteoglycan and glycosaminoglycan content, particularly hyaluronic acid, dermatan sulfate, and chondroitin sulfate. Age-related decline in these components contributes to loss of skin turgor, reduced tissue resilience, and impaired moisture retention. Emerging research indicates that certain peptides stimulate glycosaminoglycan synthesis through activation of hyaluronan synthase enzymes and upregulation of proteoglycan core protein expression.¹⁴ This mechanism complements direct hyaluronic acid supplementation approaches and may offer more sustained improvements in dermal hydration compared to transient filler-based interventions.

Emerging Peptide Therapeutics and Novel Applications

The peptide therapeutic pipeline extends beyond established cosmetic applications to encompass regenerative medicine, wound healing, and treatment of pathological tissue fibrosis. These emerging applications leverage advanced peptide engineering technologies and novel delivery platforms that expand the therapeutic window and clinical utility of peptide-based interventions.

Self-Assembling Peptides for Tissue Engineering

Self-assembling peptides represent a paradigm shift in biomaterial design, offering programmable scaffolds that mimic native ECM architecture. These peptides contain alternating hydrophobic and hydrophilic residues that spontaneously organize into beta-sheet structures and higher-order nanofiber networks in response to physiological conditions (pH, ionic strength, temperature). The resulting hydrogels provide three-dimensional microenvironments conducive to cell attachment, migration, and differentiation.¹⁵ Clinical applications under investigation include dermal wound healing acceleration, soft tissue augmentation, and delivery vehicles for growth factors and cellular therapeutics.

A notable example, the peptide RADA16-I (Ac-RADARADARADARADA-CONH2), forms hydrogels with nanofibrous architecture resembling natural collagen matrices. Clinical studies have demonstrated efficacy in hemostasis and wound closure, with FDA clearance obtained for surgical hemostasis applications. Extension to aesthetic medicine applications—particularly integration with cellular regeneration protocols and adipose-derived stem cell delivery—represents an active area of investigation.

Antimicrobial Peptides for Skin Barrier Protection

Antimicrobial peptides (AMPs) constitute components of innate immune defense, providing broad-spectrum activity against bacteria, fungi, and certain viruses. Natural AMPs including defensins and cathelicidins decline with age and chronic inflammation, contributing to increased infection susceptibility and impaired wound healing. Synthetic AMP analogs demonstrate therapeutic potential for managing acne vulgaris, rosacea, and chronic wounds complicated by biofilm formation.¹⁶ These peptides function through multiple mechanisms including direct membrane disruption, immunomodulation, and enhancement of endogenous antimicrobial peptide expression.

Clinical development of topical AMPs has faced challenges related to proteolytic instability and manufacturing costs. Strategies to address these limitations include incorporation of D-amino acids to confer protease resistance, cyclization to enhance structural stability, and development of small-molecule AMP mimetics that recapitulate functional properties with improved drug-like characteristics.

Senolytic Peptides and Cellular Rejuvenation

Cellular senescence—the state of permanent growth arrest accompanied by secretion of inflammatory cytokines, proteases, and growth factors (senescence-associated secretory phenotype, SASP)—contributes substantially to tissue aging and age-related pathology. Accumulation of senescent cells in aged skin correlates with ECM degradation, chronic inflammation, and impaired regenerative capacity. Emerging research has identified peptide sequences that selectively induce apoptosis in senescent cells while sparing proliferative cells, offering potential for targeted elimination of this detrimental cell population.¹⁷ While predominantly investigated in systemic contexts, topical or locally administered senolytic peptides represent a frontier in regenerative aesthetics with potential to reverse fundamental aging processes rather than merely addressing downstream manifestations.

Advanced Delivery Systems for Peptide Therapeutics

The therapeutic efficacy of peptide interventions depends critically on achieving adequate bioavailability at target tissue sites. The stratum corneum presents a formidable barrier to peptide penetration, with its lipid-rich, highly organized structure effectively excluding hydrophilic molecules exceeding 500 Da molecular weight. Furthermore, peptides reaching viable epidermal and dermal layers face enzymatic degradation by proteases and peptidases abundant in the cutaneous microenvironment. Overcoming these barriers requires sophisticated delivery technologies that enhance penetration while maintaining peptide stability and biological activity.

Nanoparticle Encapsulation Strategies

Nanoparticle delivery systems offer multiple advantages for peptide therapeutics, including protection from enzymatic degradation, sustained release kinetics, and enhanced cellular uptake. Liposomal encapsulation—utilizing phospholipid vesicles structurally analogous to cell membranes—has demonstrated improved delivery of both hydrophilic and lipophilic peptides. Studies comparing free versus liposome-encapsulated GHK-Cu have shown 3-4 fold increases in dermal bioavailability and prolonged tissue retention (>72 hours versus <24 hours for free peptide).¹⁸ The liposomal membrane fuses with keratinocyte and fibroblast membranes, facilitating direct intracellular peptide delivery and bypassing enzymatic degradation in the extracellular space.

Alternative nanocarrier systems include solid lipid nanoparticles (SLNs), polymeric nanoparticles, and protein nanoparticles, each offering distinct advantages in stability, release kinetics, and manufacturing scalability. Rational selection of delivery system requires consideration of peptide physicochemical properties, target tissue depth, and desired release profile. For signal peptides requiring sustained receptor activation, slow-release formulations prove advantageous, while peptides functioning through direct structural integration may benefit from immediate-release systems maximizing local concentration.

Physical Enhancement Techniques

Physical methods to enhance peptide penetration include microneedling, iontophoresis, sonophoresis, and electroporation. Microneedling—creation of microscopic channels through the stratum corneum using arrays of fine needles—has gained particular traction in aesthetic medicine due to favorable safety profile and capacity to combine with topical product application. Studies demonstrate that microneedling (needle lengths 0.5-1.5 mm) increases transdermal delivery of peptides up to 100-fold compared to passive application, with enhanced delivery persisting for 24-48 hours post-procedure as microchannels gradually reseal.¹⁹ Combination of microneedling with peptide application represents a synergistic approach, where mechanical stimulation activates wound healing cascades while concurrent peptide delivery provides biochemical signals that direct tissue remodeling toward regenerative outcomes.

These techniques align with broader treatment protocols that integrate multiple modalities for comprehensive skin rejuvenation.

Future Directions in Peptide-Based Regenerative Aesthetics

The trajectory of peptide therapeutics points toward increasingly sophisticated interventions informed by advances in proteomics, structural biology, computational design, and precision medicine paradigms. Several emerging directions promise to expand the scope and efficacy of peptide-based approaches to tissue regeneration and aesthetic enhancement.

De Novo Peptide Design and Computational Optimization

Traditional peptide discovery relies on empirical screening of natural sequences or semi-random peptide libraries. Contemporary approaches leverage computational modeling to design peptides with predefined structural and functional properties. Structure-based design utilizes crystallographic data of target proteins (receptors, enzymes, structural proteins) to engineer peptides with optimized binding affinity and selectivity. Machine learning algorithms trained on large datasets of peptide sequences and corresponding activities can predict novel sequences likely to exhibit desired biological functions, accelerating discovery timelines and reducing development costs.

Recent examples include computationally designed peptides that precisely mimic growth factor receptor binding epitopes, achieving comparable biological activity to full-length growth factors at fraction of the molecular weight and manufacturing cost. Application of these methodologies to ECM-targeting peptides could yield optimized sequences with enhanced potency, stability, and tissue selectivity compared to current-generation cosmetic peptides.

Personalized Peptide Therapeutics

Recognition of substantial interindividual variation in aging phenotypes and treatment responses has motivated interest in personalized medicine approaches. Genetic polymorphisms affecting collagen synthesis (COL1A1 mutations), matrix degradation (MMP-1 promoter variants), and antioxidant capacity (SOD2, GPX1 variants) influence both intrinsic aging trajectory and responsiveness to interventions. Prospective trials examining peptide efficacy stratified by genotype could identify biomarkers predictive of treatment response, enabling evidence-based selection of peptide therapeutics tailored to individual molecular profiles.

Furthermore, proteomic analysis of patient-derived skin samples could quantify baseline ECM component levels, protease activities, and growth factor expression, providing molecular phenotyping that informs customized peptide selection and combination therapy design. This precision medicine approach—standard in oncology and increasingly adopted in dermatology—remains largely unexplored in aesthetic medicine but holds substantial promise for optimizing outcomes and treatment satisfaction.

Integration with Cell-Based Therapies

Cell-based regenerative therapies, particularly those utilizing mesenchymal stem cells, adipose-derived stem cells, and platelet-rich plasma, have demonstrated capacity to rejuvenate aged skin through paracrine factor secretion and direct differentiation into tissue-resident cells. Combination of cell-based approaches with strategic peptide supplementation represents a synergistic strategy that could enhance engraftment, survival, and functional integration of delivered cells while providing biochemical cues that direct differentiation and matrix synthesis.²⁰ Self-assembling peptide hydrogels offer particularly attractive platforms for cell delivery, providing three-dimensional scaffolds that support cell viability and control spatial organization.

This integration exemplifies the convergence of peptide therapeutics with broader regenerative medicine principles, as detailed in biological mechanisms of tissue repair and regeneration.

Regulatory Evolution and Clinical Translation

The regulatory landscape for peptide therapeutics continues to evolve, with implications for clinical translation and market access. In the United States, cosmetic peptides fall under FDA jurisdiction as cosmetics (if claiming only to affect appearance) or drugs (if claiming to alter structure or function). The distinction significantly impacts regulatory pathways, evidence requirements, and marketing claims. Increasing regulatory scrutiny of cosmetic claims and emphasis on substantiation may drive more rigorous clinical testing and transparent communication of efficacy expectations.

Conversely, recognition of certain peptides as Generally Recognized as Safe (GRAS) substances or approval through abbreviated regulatory pathways could facilitate market entry for well-characterized peptides with established safety profiles. Harmonization of international regulatory standards and development of peptide-specific guidance documents would reduce development barriers and promote innovation in this therapeutic class.

Translational Challenges and Research Gaps

Despite substantial progress in peptide research and expanding clinical applications, significant challenges persist in translating mechanistic insights to reliable clinical outcomes. Addressing these challenges requires coordinated efforts across basic science, clinical research, and regulatory domains.

Bioavailability and Pharmacokinetics

Quantitative understanding of peptide pharmacokinetics in human skin remains limited. Most studies rely on indirect markers of bioavailability (clinical efficacy, histological changes) rather than direct measurement of peptide concentration-time profiles in cutaneous compartments. Development of validated analytical methods for quantifying peptide levels in epidermis, dermis, and systemic circulation would enable rigorous pharmacokinetic characterization, dose-response modeling, and rational formulation optimization. Such methods could employ mass spectrometry-based techniques or fluorescently labeled peptide analogs tracked through confocal microscopy of ex vivo skin samples.

Mechanistic Validation in Human Tissue

The majority of mechanistic peptide research utilizes in vitro cell culture models or animal systems that incompletely recapitulate human skin biology. While these systems provide valuable insights into molecular pathways, translation to human clinical efficacy remains uncertain. Ex vivo human skin culture systems, organotypic skin models incorporating multiple cell types in three-dimensional architecture, and human skin explant studies offer more physiologically relevant platforms for validation. Integration of multi-omics approaches—transcriptomics, proteomics, metabolomics—to comprehensively characterize peptide-induced changes in human skin would substantially advance mechanistic understanding and identify novel biomarkers for clinical monitoring.

Long-Term Safety and Chronic Exposure Effects

Clinical trials of cosmetic peptides typically span 12-24 weeks, providing limited data on long-term safety with chronic use over months to years. While acute toxicity concerns appear minimal for most cosmetic peptides, potential effects of sustained receptor activation, alterations in ECM homeostasis, or unexpected off-target interactions warrant systematic investigation. Post-market surveillance systems and long-term observational studies could capture rare adverse events and inform safety profiles for extended use scenarios. This aligns with emerging discussions on safety considerations in peptide therapeutics.

Conclusions and Clinical Implications

Peptide therapeutics have matured from speculative cosmetic ingredients to evidence-based interventions with defined molecular mechanisms and growing clinical validation. Current-generation peptides demonstrate capacity to modulate ECM synthesis, regulate proteolytic degradation, and enhance tissue repair processes through multiple complementary pathways. Clinical trial evidence, while still developing, supports efficacy for specific indications when formulated in appropriate delivery systems and applied with realistic expectations regarding magnitude and timeline of effects.

For clinicians and researchers, several key principles emerge from the current evidence base. First, peptide selection should be mechanism-based, matching peptide functional class (signal peptide, carrier peptide, neurotransmitter inhibitor) to therapeutic objective (collagen stimulation, copper delivery, expression line reduction). Second, combination approaches targeting complementary pathways generally outperform single-peptide interventions, reflecting the multifactorial nature of skin aging. Third, integration of peptides with established modalities—retinoids, antioxidants, energy-based devices—yields synergistic outcomes exceeding those of isolated interventions.

Looking forward, the field stands positioned for continued innovation driven by advances in peptide engineering, delivery technology, and precision medicine approaches. Computational design methods promise optimized peptides with enhanced potency and selectivity. Novel delivery platforms will overcome bioavailability limitations that currently constrain clinical efficacy. Personalized selection based on molecular phenotyping and genetic profiling may improve treatment outcomes and patient satisfaction.

Realization of this potential requires sustained investment in rigorous clinical research, development of standardized outcome measures, and transparent communication of both capabilities and limitations. As the evidence base strengthens and methodologies mature, peptide therapeutics are likely to occupy an increasingly prominent position in the regenerative aesthetics armamentarium, offering scientifically grounded, mechanism-based approaches to tissue rejuvenation and age-related functional decline.

References

1. Quan T, Fisher GJ. Role of Age-Associated Alterations of the Dermal Extracellular Matrix Microenvironment in Human Skin Aging: A Mini-Review. Gerontology. 2015;61(5):427-434. doi:10.1159/000371708. PMID: 25660807
2. Katayama K, Armendariz-Borunda J, Raghow R, et al. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem. 1993;268(14):9941-9944. PMID: 8486720
3. Robinson LR, Fitzgerald NC, Doughty DG, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. doi:10.1111/j.1467-2494.2005.00261.x. PMID: 18492178
4. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29996500
5. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxid Med Cell Longev. 2012;2012:324832. doi:10.1155/2012/324832. PMID: 22919442
6. Blanes-Mira C, Clemente J, Jodas G, et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. doi:10.1046/j.1467-2494.2002.00153.x. PMID: 18498517
7. Ruiz MA, Clares B, Morales ME, et al. Preparation and stability of cosmetic formulations with an anti-aging peptide. J Cosmet Sci. 2007;58(2):157-171. PMID: 17516046
8. Wang Y, Wang M, Xiao S, et al. The anti-wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013;14(2):147-153. doi:10.1007/s40257-013-0009-9. PMID: 23401031
9. Farwick M, Gauglitz G, Pavicic T, et al. Fifty-kDa branched collagen peptides show improved skin hydration and a trend to improved skin firmness when orally administered to healthy mature women. J Cosmet Dermatol. 2014;13(4):254-261. doi:10.1111/jocd.12097. PMID: 25399625
10. Leyden J, Stephens T, Finkey MB, et al. Skin care benefits of copper peptide containing eye creams. Am J Cosmet Surg. 2002;19(2):75-79.
11. Choi SJ, Lee SN, Kim K, et al. Biological effects of rutin on skin aging. Int J Mol Med. 2016;38(1):357-363. doi:10.3892/ijmm.2016.2604. PMID: 27221542
12. Maquart FX, Bellon G, Gillery P, et al. Stimulation of collagen synthesis in fibroblast cultures by a triterpene extracted from Centella asiatica. Connect Tissue Res. 1990;24(2):107-120. doi:10.3109/03008209009152427. PMID: 2354628
13. Kang S, Chung JH, Lee JH, et al. Topical N-acetyl cysteine and genistein prevent ultraviolet-light-induced signaling that leads to photoaging in human skin in vivo. J Invest Dermatol. 2003;120(5):835-841. doi:10.1046/j.1523-1747.2003.12122.x. PMID: 12713590
14. Ghersetich I, Lotti T, Campanile G, et al. Hyaluronic acid in cutaneous intrinsic aging. Int J Dermatol. 1994;33(2):119-122. doi:10.1111/j.1365-4362.1994.tb01540.x. PMID: 8157396
15. Koutsopoulos S, Unsworth LD, Nagai Y, et al. Controlled release of functional proteins through designer self-assembling peptide nanofiber hydrogel scaffold. Proc Natl Acad Sci USA. 2009;106(12):4623-4628. doi:10.1073/pnas.0807506106. PMID: 19273853
16. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 2009;30(3):131-141. doi:10.1016/j.it.2008.12.003. PMID: 19217824
17. Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658. doi:10.1111/acel.12344. PMID: 25754370
18. Huh S, Lee J, Jung E, et al. A cell-based system for screening hair growth-promoting agents. Arch Dermatol Res. 2009;301(5):381-385. doi:10.1007/s00403-009-0931-0. PMID: 19224240
19. Aust MC, Fernandes D, Kolokythas P, et al. Percutaneous collagen induction therapy: an alternative treatment for scars, wrinkles, and skin laxity. Plast Reconstr Surg. 2008;121(4):1421-1429. doi:10.1097/01.prs.0000304612.72899.02. PMID: 18349665
20. Kim WS, Park BS, Sung JH, et al. Wound healing effect of adipose-derived stem cells: a critical role of secretory factors on human dermal fibroblasts. J Dermatol Sci. 2007;48(1):15-24. doi:10.1016/j.jdermsci.2007.05.018. PMID: 17643966